← Back to Search

Free Light Chain Assessment in Twins

N/A
Waitlist Available
Led By Alan Wu, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy subjects 18-80 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one month after the completion of the enrollment
Awards & highlights
No Placebo-Only Group

Summary

This trial is recruiting identical and fraternal twins to help establish a reference range for free light chains in the blood.

Who is the study for?
This trial is for healthy adult twins, both identical and fraternal, aged between 18 to 80 years. Both twins need to participate. It's not open to individuals showing symptoms that might suggest they have multiple myeloma like kidney issues, low red blood cell counts (anemia), or bone pain.
What is being tested?
The study involves collecting a small amount of blood from each participant at San Francisco General Hospital's Clinical Lab. The purpose is to determine the normal range for free light chains in the serum of these twins.
What are the potential side effects?
Since this trial only involves drawing a small sample of blood, side effects are minimal and may include temporary discomfort at the puncture site, light-headedness, bruising or bleeding.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 80 years old and healthy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month after the completion of the enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month after the completion of the enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Free light chain reference range

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Healthy twinExperimental Treatment1 Intervention
Free light chains of twins compared to non-twin siblings
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Free light chains
2018
N/A
~40

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,918 Total Patients Enrolled
19 Trials studying Multiple Myeloma
1,100 Patients Enrolled for Multiple Myeloma
Alan Wu, PhDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
450 Total Patients Enrolled

Media Library

Free light chains Clinical Trial Eligibility Overview. Trial Name: NCT04191057 — N/A
Multiple Myeloma Research Study Groups: Healthy twin
Multiple Myeloma Clinical Trial 2023: Free light chains Highlights & Side Effects. Trial Name: NCT04191057 — N/A
Free light chains 2023 Treatment Timeline for Medical Study. Trial Name: NCT04191057 — N/A
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top